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REVIEW
Abstract: In the last decade, numerous novel ocular hypotensive agents have been introduced
for the control of intraocular pressure (IOP). Clinicians now have more options than ever in
the selection of medical therapy for the treatment of glaucoma and ocular hypertension. When
selecting an ocular hypotensive medication for their patients, clinicians should consider not
only the IOP-lowering efficacy of an agent, but also the ability of the drug to allow patients to
achieve target levels of IOP that are low enough to stop the progression of glaucomatous
damage. Other considerations should include how well the drug controls diurnal IOP, the
likelihood of serious adverse events, the versatility of the medication for use as an adjunctive
agent, as well as other potential attributes (ie, neuroprotection).
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Introduction
Glaucoma is the second leading cause of blindness worldwide (Thylefors and Négrel
1994). It is now recognized as the leading cause of blindness among African Americans
in the US (Quigley and Vitale 1997)
 and data from 6357 participants in the Los
Angeles Latino Eye Study suggest that the prevalence of open-angle glaucoma (OAG)
is higher among Latinos of Mexican ancestry than in the Caucasian population (Varma
et al 2004). It is estimated that more than 4 million people in the US have glaucoma;
130 000 of these individuals are legally blind from the disease. In addition, another
5–10 million individuals may have elevated IOP (Quigley and Vitale 1997; EDGED
2002). Risk factors for glaucoma include advanced age, African ancestry, a family
history of glaucoma, severe myopia, and ocular risk factors, such as higher intraocular
pressure (IOP), morphologic features of the optic disc, and thinness of the cornea
(Gordon et al 2002; Kass et al 2002; Kroese and Burton 2003; Jonas et al 2004;
Martus et al 2005).
Although elevated IOP is one of the most consistent risk factors for the
development or progression of glaucoma, it is no longer considered a defining
characteristic. Instead, it is now clear that the glaucomas are actually a group of
chronically progressive neuropathies characterized by atrophy of the optic nerve,
visual field deficits due to the loss of retinal ganglion cells (RGC), and cupping of
the optic nerve head (AAO 2000). Glaucoma has few subjective symptoms during a
long period early in the disease, but damage is irreversible once it occurs. Early
detection of progression and treatment are critical to limit this damage.
The established treatment paradigm for OAG and ocular hypertension (OHT)
(which is characterized by an IOP >21 mm Hg and lack of any glaucomatous changes
of the optic disc or visual field defects) has long concentrated on lowering IOP to a
level at which the progression (or onset) of glaucomatous damage is halted or delayed.
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In recent years, however, the treatment paradigm has become
considerably more aggressive. This change is due both to
the availability of more powerful ocular hypotensive agents
as well as to the increased understanding of the need to
achieve the lowest possible pressures to preserve the visual
field. Whereas successful glaucoma therapy was once
defined as an IOP reduced (with treatment) to within two
standard deviations of the mean of a normal population,
clinicians today see halting the progression of glaucomatous
damage and preserving the visual field of each patient as
the only acceptable treatment outcome.
Ophthalmologists are presently faced with a myriad of
choices for ocular hypotensive therapy. The medications
available for reducing IOP in glaucoma patients include
topical β-adrenergic antagonists (eg, timolol, betaxolol),
carbonic anhydrase inhibitors (eg, dorzolamide,
brinzolamide), cholinergics (eg, pilocarpine), α-adrenergic
agonists (eg, brimonidine), prostaglandins (eg, latanoprost,
travoprost), and prostamides (bimatoprost). Fixed
combinations of commonly used drugs have also been
developed (eg, timolol–dorzolamide and brimonidine–
timolol) and may offer benefits of convenience, cost, and
safety, but limit individualization of dosing (Fechtner and
Realini 2004). The purpose of this review is to provide an
overview of clinical efficacy, mechanism of action, safety
and tolerability profile, convenience and compliance, and
the potential for any added benefits (eg, enhancement of
ocular blood flow, neuroprotection) of frequently used
glaucoma medications.
Selecting an ocular hypotensive
agent
The selection of an ocular hypotensive agent should include
not only an evaluation of IOP-lowering efficacy, but also
the level of risk as associated with potential side effects and
complications, the mechanism of action of the drug, patient
convenience and compliance, and the possibility for added
potential benefits (such as enhancement of ocular blood flow
or neuroprotection).
Safety and tolerability is of utmost concern when
selecting any ocular hypotensive agent for chronic use.
Ocular and systemic side effects of topical ocular
medications must be identified, especially those that
seriously affect systemic health and patient quality of life.
Every drug has side effects and the risk of those side effects
must be balanced with the potential benefits arising from
lowering IOP.
Consideration of the mechanism of action of an ocular
hypotensive medication may allow for optimal treatment
outcomes, especially when selecting agents for adjunctive use.
This is important because most classes of medications lower
IOP by different mechanisms and certain combinations of these
agents may maximize efficacy. Specifically, the prostamides,
prostaglandin analogs, and parasympathomimetics increase
aqueous outflow. Beta-blockers and carbonic anhydrase
inhibitors (CAIs) suppress aqueous formation, and α-adrenergic
agonists lower IOP by both decreasing aqueous production
and increasing uveoscleral outflow. Combining a prostamide
or prostaglandin with brimonidine, for example, may maximize
IOP-lowering by combining complimentary mechanisms of
action.
Patient convenience and compliance are also important
factors in selecting an ocular hypotensive regimen. Whenever
possible, it is preferable to control IOP with a single medication
rather than multiple medications, because every medication
added to the regimen has side effects, and each added
medication increases the costs of treatment. Furthermore,
multiple medications may increase the patient’s exposure to
benzalkonium chloride (BAK), a common preservative in
ophthalmic medications packaged in multi-dose containers.
Benzalkonium chloride may accumulate in ocular tissues for a
lengthy period of time and at high concentrations, promote
cell death in a dose-dependent manner (De Saint Jean et al
1999). Patients are more likely to be compliant with their once-
a-day monotherapeutic regimen than with multiple medications
given in multiple doses (Coons et al 1994; Patel and Spaeth
1995).
Although modern treatment paradigms focus on
controlling IOP, the ultimate goal of any therapy for
glaucoma is the preservation of the RGCs. Neuronal cell
death in glaucoma occurs when the factors promoting cell
death overwhelm the factors promoting cell survival. Factors
promoting cell death include mechanical trauma, vascular
and metabolic insufficiencies, and genetic predisposition.
Factors promoting cell survival include neurotrophins,
signaling molecules from neighboring cells, and intrinsic
survival factors. The goal of neuroprotection is to slow or
prevent death of RGCs by shifting the balance back in favor
of cell survival. The potential for added benefit, in this case
neuroprotection, should be considered when selecting ocular
hypotensive therapy.Therapeutics and Clinical Risk Management 2006:2(2) 195
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Beta-blockers
Beta-blockers compete with sympathomimetic substances
for access to receptors, reducing sympathetic activity via
competitive inhibition (Zimmerman 2000). Sympathetic
activity is involved in the active secretion of aqueous via
formation of norepinephrine-β receptor complex, and beta-
blockers effectively lower IOP by decreasing the production
of aqueous. Topical beta-blockers are either nonselective
or selective, preferentially inhibiting β1 adrenoceptors
(Hoyng and van Beek 2000).
Nonselective beta-blockers act by inhibiting both β1
and β2 adrenergic receptors. Examples of nonselective
beta-blockers include levobunolol, metipranolol,
carteolol, and timolol. As a class, topical nonselective
beta-blockers are reasonably well tolerated locally. For
example, the most common ocular adverse events
associated with timolol therapy include conjunctival
hyperemia, burning, stinging, or superficial punctate
keratitis (McMahon et al 1979; Van Buskirk 1980;
Zimmerman 2000). Most ocular side effects resolve after
the medication is discontinued. Conversely, the systemic
side effects associated with topical beta-blockers may be
more serious. Topical application of beta-blockers can
lead to systemic absorption through conjunctiva and
lacrimal drainage system. Timolol may cause bradycardia,
arrhythmia, and congestive heart failure by blocking the
β1 adrenoceptors of the heart (McMahon et al 1979; van
Buskirk 1980; Hoyng and van Beek 2000). Timolol is
contraindicated in patients with pulmonary disease as
inhibition of β2 receptors in the bronchi and bronchioles
results in contraction of smooth muscle of the bronchial
tree from unopposed parasympathetic activity, leading
to bronchospasm and respiratory obstruction (McMahon
et al 1979; Fraunfelder 1980; Nelson et al 1986; Hoyng
and van Beek 2000). Further, timolol crosses the blood–
brain barrier and blocks serotonin receptors in the central
nervous system and may cause depression, weakness,
fatigue, memory loss, and decreased libido and impotence
(Zimmerman 2000). Nonselective beta-blockers should
be used with caution in patients with diabetes mellitus
(Velde and Kaiser 1983). Moreover, topical beta-blockers
may decrease plasma high density lipoprotein (HDL)
levels (Bartlett 1999). Several reports have demonstrated
that the use of topical beta-blockers may negatively
impact patients’ quality of life by causing exercise
intolerance, sexual dysfunction, and respiratory difficulty
(Zimmerman 2000; Simmons and Earl 2002).
The potential for interactions with other medications
should be considered before prescribing topical beta-
blockers, especially in elderly patients. A recent report by
Valuck (2001) found that 30.2%–45.7% of topical beta-
blocker users surveyed had a concurrent prescription for
one or more medications used to treat depression, congestive
heart failure, or chronic obstructive pulmonary disease.
Topical beta-blockers may exacerbate all of these chronic
conditions. These findings underscore the importance of a
thorough medical review before prescribing topical beta-
blockers. The concomitant administration of systemic and
topical beta-blockers may be inadvisable because of the
potential for systemic additive effects and reduced ocular
hypotensive efficacy (Schuman 2000). Caution must also
be used when prescribing a topical beta-blocker to patients
using calcium antagonists, catecholamine-depleting drugs,
digitalis and calcium antagonists, and quinidine.
Cardio-selective beta-blockers (eg, betaxolol)
preferentially inhibit β1 adrenoceptors (Zimmerman 2000).
The most frequent adverse reaction to betaxolol is stinging
upon instillation, which is minimized by an ocular
suspension with a similarly effective 2-fold reduced
concentration (0.25%). The extent of β1-adrenoreceptor
occupancy of topically applied betaxolol in the systemic
circulation is less than that of the nonselective blockers and
β2-receptor occupancy is negligible, providing a better
safety profile in patients with cardiopulmonary disease
(Yarangumeli and Kural 2004). Recent reports have
suggested that betaxolol allows, as a result of calcium and
sodium channel blocking activities, improvement of retinal
perfusion and may prevent neuronal cell death (Osborne et
al 1999, 2005).
Betaxolol lowers IOP by decreasing aqueous production,
although it has been shown to be less effective than timolol
or brimonidine (Serle 1996; Javitt and Goldberg 2000;
Nordmann et al 2002). However, there may be a possible
added potential benefit to the use of betaxolol for the
treatment of high IOP: enhanced ocular blood flow.
Interestingly, many studies evaluated the effect of betaxolol
on ocular blood flow, but with conflicting results. Turacli et
al (1998) reported that ocular hemodynamics and visual
function may be improved by long-term use of betaxolol in
patients with normal-tension glaucoma (NTG). Similarly,
Arend and associates found that betaxolol (as well as
levobunolol, and timolol) increased blood velocities in the
epipapillary and retinal capillaries, while decreasing
atriovenous passage time by approximately 25% in normalTherapeutics and Clinical Risk Management 2006:2(2) 196
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subjects (Arend et al 1998). Conversely, Harris and
colleagues (2000) reported that, while both betaxolol and
dorzolamide lowered IOP, only dorzolamide significantly
accelerated arteriovenous passage of fluorescein dye in the
inferior temporal quadrant of the retina, as measured by
scanning laser ophthalmoscopy. Additional research is
needed before a conclusion may be reached regarding the
role of ocular blood flow in the treatment of glaucoma.
Topical carbonic anhydrase inhibitors
The topical CAIs, dorzolamide and brinzolamide, are
sulfonamides that lower IOP by reducing aqueous
production (Silver 1998) and are most often used as
adjunctive therapy to other antiglaucoma agents
(Clineschmidt et al 1998; Tsukamoto et al 2005). The CAIs
reduce aqueous production less than timolol and lower IOP
to a lesser extent (Silver 1998; Wayman et al 1997).
The most commonly reported adverse events with topical
CAIs are burning and stinging, bad taste in the mouth, and
conjunctivitis. The CAIs may be contraindicated in patients
with allergies to sulfa (Zimmerman 2000). The CAIs are
most often prescribed in twice daily (BID) or thrice daily
(TID) regimens.
Cholinergic agonists
Parasympathomimetic agents, most commonly pilocarpine,
are rarely used as first-line therapy today, but are considered
third-line treatment options. When added to bimatoprost at
concentrations of 2%, 4%, and 6%, pilocarpine was reported
to be neither additive nor antagonistic to the ocular
hypotensive efficacy of bimatoprost (Toor et al 2005).
α2 adrenoceptor agonist
Brimonidine, a highly selective and potent α2 adrenoceptor
agonist, lowers IOP by a dual mechanism of action:
increasing uveoscleral outflow and decreasing aqueous
production (Toris et al 1993). Originally available as
brimonidine 0.2%, the first reformulation of brimonidine,
brimonidine purite 0.15%, provided a 25% reduction in
active ingredient and a new, gentler preservative, purite.
The latest formulation of brimonidine is currently available
as Alphagan P 0.1%, providing a 50% decrease in active
ingredient but still providing equivalent IOP lowering to
the original 0.2% solution.
Since its introduction as brimonidine 0.2% ophthalmic
solution, brimonidine has proven in clinical trials to be a
safe and effective monotherapy, adjunctive, and replacement
therapy for the long-term management of glaucoma and
OHT (Schuman et al 1997; Lee 2000; Lee et al 2000).
Clinical trials have demonstrated the efficacy of brimonidine
as both monotherapy (Serle 1996; Katz 1999) and as a highly
efficacious adjunctive agent (Simmons 2001; Simmons and
Earl 2002; Hommer et al 2003). Brimonidine has been
shown to effectively lower IOP when used as an adjunct to
latanoprost. In a comparison of the IOP-lowering efficacy
of a dual regimen of brimonidine and latanoprost with the
fixed combination of timolol and dorzolamide, the dual
regimen of brimonidine and latanoprost provided
significantly greater mean IOP reductions than did the fixed
combination of timolol/dorzolamide (Zabriskie et al 2000).
In a post-hoc analysis of 554 patients who received
brimonidine BID as adjunctive therapy to latanoprost,
patients achieved an additional 32.2% (5.9 mm Hg) IOP
reduction when brimonidine was added to latanoprost
monotherapy (p<0.001). When brimonidine was added to
an ongoing treatment regimen of latanoprost plus one or
more ocular hypotensive medications, brimonidine provided
additional IOP reductions ranging from 15.5% (3.6 mm Hg,
p<0.002) to 20.1% (6.6 mm Hg, p<0.001) (Lee et al 2000).
An earlier post-hoc analysis of this same open-label
community study with 554 patients concluded that
brimonidine effectively lowered overall mean IOP from
baseline when used as monotherapy, combination, or
replacement therapy (Lee 2000).
Brimonidine 0.2% significantly reduced IOP from
baseline in 23 patients with uncontrolled primary open angle
glaucoma (POAG) when used adjunctively with
dorzolamide. Overall mean IOP reduction was 5.6±1.9 mm
Hg over a one-year period and was well tolerated by the
patients (Ozturk et al 2005).
 In addition, the additive effect
of brimonidine 0.2% in 40 POAG patients uncontrolled on
fixed combination of timolol–dorzolamide was shown to
reduce peak/trough IOPs significantly. Brimonidine in
combination with timolol–dorzolamide reduced the mean
peak/trough IOP by 3.9/2.9 mm Hg and 4.6/2.9 mm Hg
(Akman et al 2005).
The IOP lowering efficacy of brimonidine–purite 0.15%,
which contains 25% less active drug than the 0.2%
formulation, has been shown to be comparable with
brimonidine 0.2% when used as monotherapy in the
treatment of glaucoma and OHT (Katz 2002).
 The
preservative in the original formulation, BAK, has been
replaced with purite. Benzalkonium chloride, the most
common antimicrobial preservative used in topical multi-
use ophthalmic preparations, may be more toxic than otherTherapeutics and Clinical Risk Management 2006:2(2) 197
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preservatives at high concentrations (Berdy et al 1992;
Pissella et al 2000). It can accumulate and remain in ocular
tissue for relatively lengthy periods, and may induce cell
death in a dose-dependent manner (Gasset et al 1974; De
Saint Jean et al 2000). Patients may be taking multiple
glaucoma medications to treat this chronic disease and these
patients may be exposed to high concentreations of BAK
with potentially detrimental ocular effects (Grant and
Schuman 1990; Debbasch et al 2000). Conversely, purite is
a stabilized oxychloro complex and oxidative preservative
which is converted to natural tear components, sodium and
chloride ions, oxygen, and water (Masschelein 1979; Rozen
et al 1998). It is a microbicide with a wide spectrum of
antimicrobial activity and a very low level of toxicity in
mammalian cells (Grant et al 1996). Beyond offering a more
gentle preservative, animal studies also suggest that
brimonidine tartrate has enhanced ocular bioavailability
when formulated with purite (Dong et al 2004) and it has
been hypothesized that the similarity of IOP-lowering
provided with the smaller amount of active drug may be
due to this increased bioavailability due to the near-neutral
pH in the reformulation (Acheampong et al 2002).
Brimonidine purite 0.15% has been shown to have 41%
lower rates of ocular allergy than the original brimonidine
(Katz 2002).
The newest member of the brimonidine family,
brimonidine Purite
® 0.1% contains 50% less active drug
than the original 0.2% formulation while providing
equivalent IOP lowering. Brimonidine tartrate ophthalmic
solution 0.1% is indicated for lowering IOP in patients with
open-angle glaucoma or OHT. A multicenter, double-
masked, randomized, parallel trial was conducted to
compare the IOP lowering efficacy of brimonidine P 0.1%
with brimonidine 0.2% (Data on file, Allergan, Irvine CA,
USA). Patients were 18 years or older with need for bilateral
treatment of elevated IOP ≤ 22 mm Hg or ≤ 34 mm Hg
(asymmetry of IOP between eyes of ≤ 5mm Hg). Patients
were stratified into 2 groups based on average IOP of both
eyes at baseline (≤ 25 mm Hg or >25 mm Hg) to ensure equal
baseline IOPs. Patients in each group were then randomized
with equal allocation into one of two treatment arms. 215
patients were randomized to brimonidine P 0.1% TID and
218 to brimonidine tartrate 0.2% TID. Mean change from
baseline IOP at each timepoint ranged from −2.7mm Hg to
−5.4 mm Hg with brimonidine P
 0.1% and from −2.3 mm
Hg to –5.3 mm Hg with brimonidine tartrate 0.2%. Mean
IOP reductions from baseline were statistically significant
at each timepoint for both groups (p<0.001).
In addition to demonstrated efficacy and availability of
a preferred preservative, brimonidine may offer the added
benefit of neuroprotection. Experimental models have
shown brimonidine to have neuroprotective properties
(Yoles et al 1999; Wheeler et al 2001, 2003; WoldeMussie
et al 2001). In order to be considered a neuroprotective agent
for treating glaucoma, four criteria must be met and
brimonidine meets three of these four: (1) brimonidine
receptors are present in the retina and binding to these
receptors activates mechanisms of neuronal survival in
animal models (Wheeler et al 2001); (2) the neuroprotective
activity of brimonidine has been demonstrated in animal
models and supported by cell culture models (Yoles et al
1999; Wheeler et al 2001, 2003; WoldeMussie et al 2001);
(3) following clinical dosing, brimonidine achieves
concentrations at the retina sufficient to bind to and trigger
the α2-receptors responsible for neuroprotective activity
(Kent et al 2001); (4) neuroprotective activity should be
demonstrated in clinical trials. This fourth criterion is
currently being evaluated in clinical trials.
Brimonidine has not been shown to exert any clinically
significant effects on heart rate or blood pressure. The most
commonly-reported adverse event with brimonidine therapy
is ocular allergy and associated side effects are reversible
upon discontinuation. Studies show that brimonidine 0.2%
has a lower risk of systemic adverse events than topical β-
blockers (Serle 1996; Schuman 1996; Schuman et al 1997;
Le Blanc 1998; Javitt and Goldberg 2000) and a lower risk




Latanoprost is a biologically inactive prodrug of a
prostaglandin F2α (PGF2α) analogue with selective FP
receptor agonist activity that lowers IOP by enhancing
uveoscleral outflow (Toris et al 1993).
Latanoprost, a once-daily (QD) drug, is a potent ocular
hypotensive agent. Latanoprost has been shown to provide
IOP lowering superior to that provided by timolol (Sihota
et al 2003, 2004). The mean IOP reduction with latanoprost
in long-term studies (>6 months) has typically ranged from
25% to 34% (Camras 1996; Mishima et al 1996; Watson
and Stjernschanz 1996). A large-scale 3-month clinical trial
by Parrish and associates (2003) compared the IOP lowering
efficacy of latanoprost with that of bimatoprost and
travoprost. There were no significant among-groupTherapeutics and Clinical Risk Management 2006:2(2) 198
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differences in mean IOP reduction in the intent-to-treat
population, but bimatoprost consistently lowered IOP to a
greater extent than did either latanoprost or timolol.
Latanoprost is a versatile drug and has demonstrated efficacy
when used as adjunctive therapy to beta-blockers,
brimonidine, and cholinergic agonists (Walters et al 2000;
Zabriskie et al 2000; Toris et al 2002).
Several studies have demonstrated that a substantial
percentage of patients may be nonresponsive to latanoprost
therapy. A study by Scherer (2002) reported that
approximately 25% of patients were nonresponsive to
latanoprost (defined as a <20% reduction in IOP). Further,
in an evaluation of the efficacy of latanoprost compared
with bimatoprost, 38% to 50% of patients failed to achieve
an IOP reduction >20% after 6 months of latanoprost therapy
(Noecker, Dirks, et al 2003).
Latanoprost is generally safe and well tolerated. Mild
conjunctival hyperemia has been shown to be the most
common adverse event, with an incidence of up to 31%.
Hyperpigmentation of the irides has been reported with 3–
12 months of latanoprost therapy and is more common in
patients with irides of mixed color (Camras et al 1996; Chiba
et al 2003, 2004). Hypertrichosis and hyperpigmentation
of the eyelashes is also a relatively common side effect of
long-term latanoprost therapy (Johnstone et al 1997; Chiba
et al 2004). Serious adverse events associated with
latanoprost therapy are rare but include anterior uveitis and
cystoid macular edema in susceptible patients (Fechtner et
al 1998; Warwar et al 1998). A 5-year, multi-center, clinical
trial found latanoprost therapy to be safe and well tolerated
(Alm et al 2004). However, several reports have suggested
that latanoprost therapy may be associated with reactivation
of latent herpes simplex keratitis (Wand et al 1999; Morales
et al 2001).
A double-masked, 2-period crossover study in black and
white patients showed intraocular pressure after treatment
with latanoprost was lower than that after timolol treatment
in black patients with primary open-angle glaucoma or OHT.
At 1 of 2 timepoints, latanoprost caused a significantly
greater reduction of IOP in black patients than in white
patients (Kitnarong et al 2004).
Unoprostone isopropyl 0.15%
Unoprostone isopropyl is a decosanoid that demonstrates
weak agonist activity for FP receptors and almost no affinity
for EP1 and EP2 receptors (Goh and Kishino 1994; Hoyng
and van Beek 2000). Unoprostone lowers IOP primarily by
increasing uveoscleral outflow, but may also slightly
increase trabecular outflow (Sakurai et al 1993; Taniguchi
et al 1996).
The clinical efficacy of unoprostone is reported to be
similar to that of timolol but less than that of latanoprost
(Azuma et al 1993; Yamamoto et al 1997). The dosing
recommendation is BID. Most large-scale evaluations of
the efficacy of unoprostone have been conducted in Japan.
This homogeneity of patient populations makes it difficult
to extrapolate the IOP lowering provided by unoprostone
to ethnically diverse populations.
Unoprostone is generally well tolerated with conjunctival
hyperemia the most commonly reported adverse event,
occurring in 4% to 12% of patients. More seriously, corneal
erosion has been reported in 3% to 5% of patients
(Yamamoto et al 1997). The incidence of iridial pigmentation
induced by unoprostone is high in the case of long-term
treatment (Chiba et al 2003).
Several clinical trials have reported that unoprostone
may improve ocular blood flow by decreasing vascular
resistance. Further, a possible antagonistic effect between
endothelin 1 and unoprostone in the choroidal vasculature
has been reported (Polska et al 2002).
Travoprost
The clinical efficacy of travoprost, a synthetic
prostaglandin F2α-receptor agonist, has been reported in
several clinical trials. A 12-week, open-label study in
1590 patients conducted at 219 sites in Switzerland
reported in patients previously treated with a single drug,
travoprost decreased IOP to pressures below those
achieved on prior therapy. In all groups, travoprost
reduced mean IOP below 18 mm Hg with 1 month of
starting therapy, and control was maintained for at least
3 months (Przydryga et al 2004).
 A 12-month comparison
of travoprost, latanoprost, and timolol reported travoprost
to be more effective than timolol and as effective as
latanoprost at several time points (Netland et al 2001).
Diurnal mean reductions in IOP ranged from 6.6 mm Hg
to 8.1 mm Hg with travoprost. A study by Parrish et al
(2003) reported a mean IOP lowering of 8.0 mm Hg with
travoprost, versus 8.6 mm Hg with latanoprost, and
8.7 mm Hg with bimatoprost. Travoprost has also been
shown to provide additive IOP lowering when used as
an adjunct to timolol (Orengo-Nania et al 2001).
A phase III clinical trial comparing travoprost with
timolol and latanoprost
 suggests that travoprost is moreTherapeutics and Clinical Risk Management 2006:2(2) 199
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effective in black patients than in white patients (Netland et
al 2001). The mean reduction in IOP from baseline in this
study ranged from 6.3 mm Hg to 7.9 mm Hg in white patients
randomized to travoprost 0.004%, compared with mean IOP
reductions of 6.9 mm Hg to 8.9 mm Hg in black patients
randomized to the same treatment. At several measurements,
travoprost provided significantly lower mean IOP in black
patients than either latanoprost or timolol.
Travoprost is prescribed as a QD medication and has
been reported to be safe and well tolerated. The most
commonly reported adverse event is conjunctival hyperemia
(Parrish et al 2003).
Prostamides
Bimatoprost
Bimatoprost is a synthetic prostamide analog that lowers
IOP by a dual mechanism: primarily by increasing pressure-
dependent (presumed trabecular meshwork) outflow, but
also by increasing pressure-independent (presumed
uveoscleral) outflow (Brubaker et al 2001).
Bimatoprost has been shown to control IOP throughout
the day, maintaining a flat diurnal curve (Coleman et al 2003;
Walters et al 2004; Konstas et al 2005). The pooled 12-
month results of two trials comparing QD bimatoprost with
BID timolol reported that bimatoprost provided significantly
greater mean IOP reductions from baseline than timolol at
every time of the day and at each study visit, including the
10 AM time point of peak timolol effect (Higginbotham et
al 2002). A 12-month extension of these two studies again
showed bimatoprost caused significantly greater mean
reduction from baseline IOP than timolol at each
measurement at each study visit (Cohen et al 2004). Patients
were also significantly more likely to achieve low target
pressures with bimatoprost than with timol. These results
are consistent with earlier trials (Sherwood and Brandt 2001;
Brandt et al 2001). These findings also demonstrate that the
IOP lowering provided by bimatoprost is sustained with
long-term use.
The efficacy of bimatoprost has also been compared with
that of latanoprost (Noecker, Dirks, et al 2003). In a 6-month,
multi-center, randomized, investigator-masked trial
comparing QD bimatoprost with QD latanoprost as
monotherapy, more patients achieved low target pressures
at all times of the day in the bimatoprost group than the
latanoprost group. The target pressure analysis in this study
suggests that bimatoprost may reduce the risk of disease
progression in more glaucoma and OHT patients than does
latanoprost. A decrease in IOP of 15% to 20% from baseline
is frequently used to define a clinically relevant response to
a glaucoma medication (Alm et al 1995; Simmons et al 2000;
Nordmann et al 2002)
 and, in this study, the responder rate
at 6 months was statistically significantly higher in the
bimatoprost group than the latanoprost group at all times
measured regardless of whether a therapeutically relevant
response was defined as a 15% or 20% IOP decrease. The
results of this study were consistent with those of earlier
trials in which bimatoprost was more effective than
latanoprost in lowering IOP at all time points and statistically
superior in achieving low target pressures (DuBiner et al
2001; Gandolfi et al 2001). More recent studies also suggest
a trend for greater efficacy of bimatoprost over latanoprost
(Waters et al 2004; Simmons et al 2004; Konastas et al 2005).
The IOP lowering efficacy of latanoprost was compared
with that of bimatoprost and travoprost in a large scale 12-
week clinical study by Parrish and colleagues (2003). There
were no significant among-group differences in mean IOP,
but it was concluded that all were potent IOP-lowering
treatments. A more recent study reported that both
bimatoprost and travoprost provided significant mean IOP
reductions from baseline after 6 months of therapy in
patients with glaucoma or OHT. Bimatoprost provided
greater mean reductions and more patients achieved low
target pressures (Cantor 2001). Bimatoprost has also been
shown to be as effective as travoprost in black patients
(Noecker, Earl, et al 2003).
Bimatoprost has also been shown to be an effective
replacement therapy. Patients with open-angle glaucoma or
OHT inadequately controlled by topical beta-blocker
monotherapy were evaluated in an open-label, 12-week
study and were more likely to achieve low target pressures
with bimatoprost during both follow-up visit. Bimatoprost
reduced IOP 4.5 mm Hg (21.5%; p<0.001) from baseline at
week 6 and 4.2 mm Hg (19.6%; p<0.001) at week 12
(Quinones and Earl 2004).
Bimatoprost has been proven to be safe and well tolerated
(Cantor 2001; DuBiner et al 2001; Gandolfi et al 2001;
Orengo-Nania et al 2001; Sherwood and Brandt 2001;
Higginbotham et al 2002; Noecker, Dirks, et al 2003). The
most common reported side effects of bimatoprost therapy
are trace or mild hyperemia and eyelash growth (Sherwood
and Brandt 2001; Higginbotham et al 2002; Abelson et al
2003). A 3-month comparison trial of bimatoprost and
latanoprost reported both study medications were well
tolerated. Mild conjunctival hyperemia and eyelash growth
occurred more often with bimatoprost, while headache wasTherapeutics and Clinical Risk Management 2006:2(2) 200
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more commonly reported with latanoprost (Gandolfi et al
2001). Bimatoprost is associated with a low incidence of
increased iris pigmentation, 1.5% of patients after 1 year of
treatment (Higginbotham et al 2002), and some patients may
experience increased pigmentation of the eyelashes and
periorbital tissue. Furthermore, a two-year study with
bimatoprost reported an excellent safety profile with no
reports of increased iris pigmentation, and no reports of
uveitis or cystoid macular edema (CME) (Cohen et al 2004).
As with latanoprost, bimatoprost may be associated with
the development of CME in high-risk patients (Wand and
Gaudio 2002).
 There has also been a case report of herpes
simplex virus keratitis reactivation in a patient treated with
bimatoprost for 1 month. Although a causal relationship was
not proven, bimatoprost should be used with caution in




The fixed combination of dorzolamide (a sulfonamide and
CAI) and timolol (a nonselective beta-blocker) has been
marketed in recent years as the brand-name drug Cosopt
®.
The fixed combination provides IOP lowering superior to
that provided by monotherapy with either of its components
but somewhat less than the concomitant administration of
those components (prescribing information). Mean IOP
reduction with the combination therapy has been reported
to range from 1.5 mm Hg to 4.2 mm Hg at trough drug effect
and from 4.9 mm Hg to 5.4 mm Hg at peak (Bacharach et al
2003; Solish et al 2004). The most commonly reported
ocular adverse events are burning and stinging, but the
potential for the serious systemic side effects (eg
cardiovascular effects) exist because of the beta-blocker
component (Clineschmidt et al 1998).
Travoprost–timolol fixed combination
Two 3-month studies comparing the concomitant use of
travoprost 0.004% and timolol 0.5% with the fixed
combination of travoprost/timolol reported comparable
clinically relevant IOP reductions in patients with OAG and
OHT. The fixed combination significantly lowered IOP by
7 mm to 9 mm, similar to the IOP reductions observed with
concomitant therapy. The most frequent ocular adverse event
was hyperemia that occurred in 14.3% and 23.4% of patients
treated with travoprost/timolol combination and concomitant
travoprost–timolol, respectively (Hughes et al 2005;
Schuman et al 2005). When comparing the fixed
combination to treatment with either travoprost or timolol
alone in patients with OAG or OHT, two 3-month studies
reported clinically relevant IOP reductions that were greater
with fixed combination therapy than those produced by
either travoprost or timolol alone (Barnebey et al 2005;
Schuman et al 2005).
Brimonidine–timolol fixed combination
The fixed combination of brimonidine–timolol was well
tolerated and provided significantly better IOP control when
compared in a study with either brimonidine or timolol alone
in patients with OAG or OHT. The mean decrease from
baseline IOP ranged from 4.9 mm Hg to 7.6 mm Hg with
brimonidine–timolol, from 3.1 mm Hg to 5.5 mm Hg with
brimonidine, and from 4.3 mm Hg to 6.2 mm Hg with
timolol. Mean IOP reductions from baseline were
significantly larger with fixed brimonidine–timolol than with
timolol at all follow-up measurements (p≤0.026); the
difference was greater than 1.5 mm Hg at 10 AM, peak effect
for each treatment. Mean IOP reductions from baseline were
significantly larger with the fixed combination than with
brimonidine at 8 AM, 10 AM, and 3 PM (p<0.001); the
difference was greater than 1.5 mm Hg (Craven et al 2005).
Another 3-month study compared the fixed combination
of brimonidine–timolol with the concomitant use of the
components in 371 patients with OAG or OHT. During
follow-up, the mean reduction from baseline IOP was
significant (p<0.001) at all time points and ranged from
4.4 mm Hg to 5.3 mm Hg in each group. The fixed
combination was as effective as concomitant therapy with
respect to mean IOP and mean change from baseline IOP at
all time points and visits. No significant between-group
differences were found. Both treatments were well tolerated
with no difference in adverse events between groups (Goni
2005).
Latanoprost–timolol fixed combination
The fixed combination of prostaglandin latanoprost 0.005%
and the beta-blocker timolol 0.5% combines two
mechanisms of action, latanoprost increases uveoscleral
outflow whereas timolol decreases the formation of aqueous
humor in the ciliary epithelium. Due to the mechanism of
action of latanoprost, QD dosing of the fixed combination
resulted in slightly greater additional IOP reduction
compared with either drug administered separately. The
fixed combination has a safety profile similar to that of itsTherapeutics and Clinical Risk Management 2006:2(2) 201
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individual components, and provides a convenient
alternative for the treatment of patients uncontrolled by
monotherapy (Feldman 2004).
A 6-week study compared the fixed combination
latanoprost–timolol, given once each evening, with the
concomitant use of brimonidine and timolol, given BID, in
patients with POAG and OHT. All patients were begun on
timolol alone BID for 1 month prior to randomization. The
study found that in 32 patients the IOP diurnal curve on
timolol alone (20.9±2.8 mm Hg) decreased to 17.9±3.2 mm
Hg when patients were treated with latanoprost–timolol and
to 19.0±2.4 mm Hg when treated with brimonidine and
timolol (p=0.02). Intraocular pressures at individiual time-
points were statistically similar between the groups at the
8 AM trough and 2 and 4 hours after dosing. However,
beyond 4 hours after dosing, the fixed combination-treated
patients demonstrated a trend towards lower IOPs at each
2-hour time-point that was not statistically significant after
a Bonferroni correction (p≤0.05). Reported side effects were
similar between groups (Stewart et al 2003). A recent 6-
month study compared the fixed combination of latanoprost–
timolol with concomitant use of brimonidine and timolol in
325 patients. At the 6 month visit, mean IOP was
16.9(standard deviation [SD] 2.8)mm Hg in the fixed
combination group and 18.2(SD 3.1) mm Hg in the
brimonidine–timolol group (p<0.001) (Garcia-Sanchez et
al 2004).
Another comparison study between two fixed
combinations, latanoprost–timolol and dorzolamide–
timolol, found latanoprost–timolol slightly more effective
than that of dorzolamide–timolol in reducing mean diurnal
IOP. The mean difference was 1.00 mm Hg (95% confidence
interval, 0.31–1.69; p=0.005) in favor of the latanoprost–
timolol fixed combination. Both treatments were well
tolerated (Shin et al 2004).
Discussion
The management of OAG and OHT will evolve as we gain
knowledge of the pathophysiology of glaucoma. Today,
however, the primary objective of any pharmacological
treatment regimen for glaucoma is the preservation of the
visual field through the early and aggressive reduction of
IOP. To accomplish this objective, a target IOP should be
identified, or upper limit IOP expected to slow or stop optic-
nerve damage. Although there is no single IOP above which
a patient will always progress and below which a patient
never will, a target <17 mm Hg is likely to be low enough
to preserve the visual field of most patients. Furthermore,
because large diurnal fluctuations are a risk factor for
glaucomatous progression, this target pressure must be
controlled throughout the day.
With a target pressure in mind, the ultimate therapeutic
selection should be the option that offers the greatest
potential benefit when efficacy, side effect risk, quality of
life, and cost are considered. An optimal agent is one that
produces clinically significant reductions in IOP, allows
patients to achieve target levels of IOP at which the
progression of glaucomatous damage is halted and the visual
field preserved, controls diurnal IOP fluctuations, has a
favorable adverse event profile, is convenient to use with a
dosing regimen patients are likely to follow, exposes patients
to the least amount of BAK, and finally, presents the
possibility for potential additional benefits beyond IOP
control.
Topical beta-blockers have long been used to reduce IOP
in patients with glaucoma or OHT, but their side effect
profile may make them undesirable for use in many patients.
Topical CAIs may not provide adequate IOP lowering in
many patients and their more frequent dosing schedules may
limit patient compliance. The equivocal potential of CAIs
to enhance ocular blood flow may provide an added benefit.
Brimonidine, a highly selective alpha2 adrenergic
agonist, has proven highly effective as monotherapy,
adjunctive therapy, and replacement therapy for lowering
IOP in patients with glaucoma and OHT. The efficacy of
brimonidine has been shown to be sustained for over 4 years
in a clinical trial. The recent introduction of brimonidine P
0.1% provides clinicians another treatment option for
effective IOP-lowering. This new formulation contains 50%
less active ingredient than the original brimonidine 0.2%
formulation, but continues to provide equivalent efficacy.
Brimonidine as monotherapy provides IOP lowering
comparable with that provided by nonselective beta-blockers
and is superior to topical CAIs, and selective beta-blockers.
Brimonidine has provided significant IOP reductions when
used adjunctively to topical beta-blockers and when used
as a dual regimen with the prostaglandin prodrug
latanoprost. Brimonidine is most often dosed BID and
provides a convenient dosing schedule. Brimonidine is safe
and effective, with the most commonly reported side effect
being ocular allergy.
Latanoprost, a prostaglandin prodrug, has been proven
in numerous clinical trials to be an effective IOP-lowering
agent, but several studies have reported that a significant
percentage of patients fail to respond to latanoprost therapyTherapeutics and Clinical Risk Management 2006:2(2) 202
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(Scherer 2002; Noecker, Dirks, et al 2003 ). Latanoprost is
dosed QD and provides a convenient dosing schedule.
Compared with bimatoprost, latanoprost may have a greater
incidence of intraocular adverse events (CME, iris
pigmentation changes, uveitis) whereas adverse events
associated with bimatoprost are most often extraocular, (eg,
hyperemia and itching).
Unoprostone, which is dosed BID, has been shown to
be less efficacious than latanoprost, although, additional
studies are needed to determine the true IOP-lowering
efficacy of this drug in a non-Japanese population. The use
of unoprostone has been associated with several potentially
serious adverse events, including corneal epithelial defects.
Unoprostone may possibly potentially provide a potentially
added benefit of ET-1 effects, but further study is needed.
Travoprost, a prostaglandin, appears to provide IOP-
lowering comparable with that provided by latanoprost.
There is evidence that travoprost may be more effective in
black patients than in white patients. The most commonly
reported adverse event with travoprost is conjunctival
hyperemia.
The prostamide bimatoprost allows many patients to
achieve the low target pressures most likely to preserve the
visual field. The most common side effect of bimatoprost
therapy is conjunctival hyperemia. Bimatoprost provides
low, stable IOP throughout the day and night, and the
efficacy is sustained with long-term use. Bimatoprost is very
effective in both monotherapy and adjunctive therapy. The
most common side effect with bimatoprost therapy is mild
conjunctival hyperemia.
The various fixed combinations of timolol with
dorzolamide, travoprost, brimonidine, and latanoprost have
been shown to provide clinically relevant IOP-lowering in
a more convenient form than the concomitant administration
of its components. Fixed combinations offer benefits of cost,
convenience, and safety, but limit individualization of dosing
(Fechtner and Realini 2004).
Conclusions
Based on the data available today, glaucoma is a disease of
significant morbidity, but one that can be effectively
prevented and/or treated in many patients. With the variety
of pharmacologic agents and classes available, physicians
have more options for IOP-lowering than ever before.
Effective treatment calls for the selection of IOP-lowering
agents that will allow each patient to safely achieve a target
pressure at which their visual field is preserved, while
maximizing patient convenience and comfort, and providing
the potential for additional benefits such as neuroprotection.
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